SmithKline Beecham has been granted approval in Germany for Infanrix+DTPa+Hib, the first vaccine to be cleared for marketing which combines diphtheria, tetanus and acellular pertussis with Hemophilus influenzae in one injection.
SB said that the new combination will meet the needs of both parents and physicians, as it is the first product to protect against all four diseases in one injection. Infanrix without Hib is already marketed in 11 countries, including Germany, Italy, Belgium, Sweden and Switzerland, and has been backed for approval in the USA. An Infanrix vaccine incorporating DTPa and hepatitis B is under review by the European Medicines Evaluation Agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze